NCT00809237View on ClinicalTrials.gov

Hydroxychloroquine and Gefitinib to Treat Lung Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Gefitinib, Hydroxychloroquine

Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose

Trial Locations (1)

119074

RECRUITING

National University Hospital, Singapore

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

National University Hospital, Singapore

OTHER